Faron Change To Operating Activities vs Capital Expenditures Analysis

FARN Stock

165.00 10.00 5.71%

Faron Pharmaceuticals financial indicator trend analysis is much more than just examining Faron Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Faron Pharmaceuticals is a good investment. Please check the relationship between Faron Pharmaceuticals Change To Operating Activities and its Capital Expenditures accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Faron Pharmaceuticals Oy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Change To Operating Activities vs Capital Expenditures

Change To Operating Activities vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Faron Pharmaceuticals Change To Operating Activities account and Capital Expenditures. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Faron Pharmaceuticals' Change To Operating Activities and Capital Expenditures is -0.18. Overlapping area represents the amount of variation of Change To Operating Activities that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Faron Pharmaceuticals Oy, assuming nothing else is changed. The correlation between historical values of Faron Pharmaceuticals' Change To Operating Activities and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Operating Activities of Faron Pharmaceuticals Oy are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Change To Operating Activities i.e., Faron Pharmaceuticals' Change To Operating Activities and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

-0.18

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Change To Operating Activities

Capital Expenditures

Capital Expenditures are funds used by Faron Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Faron Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most indicators from Faron Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Faron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Faron Pharmaceuticals Oy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling General Administrative is likely to gain to about 9.1 M in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	235K	1.4M	2.2M	2.3M
Depreciation And Amortization	306K	300K	197K	185.2K

Interest Expense Depreciation And Amortization

Faron Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Non Current Assets Total	Long Term Debt	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Net Tangible Assets	Short Long Term Debt	Cash	Cash And Short Term Investments
Total Assets		0.21	0.7	0.49	0.27	0.38	-0.59	-0.42	0.42	0.25	0.24	0.67	0.68	0.4	0.24	0.79	0.36	0.4	1.0	-0.04	-0.43	0.75	0.34	-0.44	0.98	0.98
Short Long Term Debt Total	0.21		0.26	0.86	-0.85	0.68	0.65	-0.85	0.88	0.55	0.99	0.16	0.24	0.74	0.99	0.19	0.86	0.95	0.19	0.88	0.14	0.38	-0.81	0.67	0.19	0.19
Other Current Liab	0.7	0.26		0.61	-0.06	0.7	-0.26	-0.62	0.46	0.46	0.31	0.82	0.55	0.6	0.33	0.89	0.45	0.51	0.69	0.05	-0.59	0.77	-0.01	-0.37	0.61	0.61
Total Current Liabilities	0.49	0.86	0.61		-0.68	0.86	0.34	-0.95	0.98	0.58	0.85	0.56	0.45	0.8	0.86	0.55	0.91	0.97	0.48	0.74	-0.3	0.67	-0.58	0.38	0.44	0.44
Total Stockholder Equity	0.27	-0.85	-0.06	-0.68		-0.6	-0.92	0.71	-0.71	-0.46	-0.83	0.02	0.07	-0.6	-0.84	0.09	-0.72	-0.77	0.29	-0.87	-0.18	-0.1	0.98	-0.81	0.3	0.3
Current Deferred Revenue	0.38	0.68	0.7	0.86	-0.6		0.3	-0.92	0.79	0.35	0.68	0.6	0.32	0.87	0.71	0.62	0.78	0.82	0.37	0.47	-0.4	0.54	-0.54	0.16	0.3	0.3
Net Debt	-0.59	0.65	-0.26	0.34	-0.92	0.3		-0.41	0.4	0.29	0.63	-0.32	-0.35	0.34	0.63	-0.38	0.42	0.49	-0.61	0.74	0.43	-0.26	-0.95	0.87	-0.61	-0.61
Retained Earnings	-0.42	-0.85	-0.62	-0.95	0.71	-0.92	-0.41		-0.9	-0.46	-0.85	-0.48	-0.4	-0.92	-0.87	-0.58	-0.87	-0.94	-0.41	-0.68	0.21	-0.64	0.64	-0.32	-0.35	-0.35
Accounts Payable	0.42	0.88	0.46	0.98	-0.71	0.79	0.4	-0.9		0.53	0.86	0.45	0.39	0.74	0.86	0.42	0.93	0.96	0.4	0.79	-0.25	0.6	-0.62	0.47	0.38	0.38
Non Current Assets Total	0.25	0.55	0.46	0.58	-0.46	0.35	0.29	-0.46	0.53		0.57	0.47	0.16	0.4	0.56	0.34	0.45	0.59	0.21	0.45	-0.18	0.33	-0.44	0.28	0.21	0.21
Long Term Debt	0.24	0.99	0.31	0.85	-0.83	0.68	0.63	-0.85	0.86	0.57		0.19	0.25	0.76	1.0	0.23	0.86	0.95	0.22	0.85	0.14	0.41	-0.8	0.62	0.22	0.22
Net Receivables	0.67	0.16	0.82	0.56	0.02	0.6	-0.32	-0.48	0.45	0.47	0.19		0.19	0.47	0.2	0.82	0.38	0.41	0.66	-0.05	-0.75	0.55	0.07	-0.35	0.58	0.58
Common Stock Total Equity	0.68	0.24	0.55	0.45	0.07	0.32	-0.35	-0.4	0.39	0.16	0.25	0.19		0.32	0.26	0.46	0.41	0.38	0.68	0.16	-0.22	0.79	0.16	-0.23	0.7	0.7
Common Stock Shares Outstanding	0.4	0.74	0.6	0.8	-0.6	0.87	0.34	-0.92	0.74	0.4	0.76	0.47	0.32		0.78	0.58	0.74	0.82	0.39	0.51	-0.09	0.56	-0.57	0.2	0.36	0.36
Non Current Liabilities Total	0.24	0.99	0.33	0.86	-0.84	0.71	0.63	-0.87	0.86	0.56	1.0	0.2	0.26	0.78		0.24	0.87	0.95	0.22	0.84	0.12	0.42	-0.81	0.6	0.22	0.22
Other Current Assets	0.79	0.19	0.89	0.55	0.09	0.62	-0.38	-0.58	0.42	0.34	0.23	0.82	0.46	0.58	0.24		0.33	0.43	0.79	-0.07	-0.6	0.68	0.15	-0.46	0.69	0.69
Other Stockholder Equity	0.36	0.86	0.45	0.91	-0.72	0.78	0.42	-0.87	0.93	0.45	0.86	0.38	0.41	0.74	0.87	0.33		0.93	0.34	0.71	-0.27	0.6	-0.65	0.39	0.35	0.35
Total Liab	0.4	0.95	0.51	0.97	-0.77	0.82	0.49	-0.94	0.96	0.59	0.95	0.41	0.38	0.82	0.95	0.43	0.93		0.38	0.81	-0.12	0.58	-0.71	0.49	0.35	0.35
Total Current Assets	1.0	0.19	0.69	0.48	0.29	0.37	-0.61	-0.41	0.4	0.21	0.22	0.66	0.68	0.39	0.22	0.79	0.34	0.38		-0.06	-0.43	0.74	0.36	-0.45	0.98	0.98
Short Term Debt	-0.04	0.88	0.05	0.74	-0.87	0.47	0.74	-0.68	0.79	0.45	0.85	-0.05	0.16	0.51	0.84	-0.07	0.71	0.81	-0.06		0.27	0.27	-0.81	0.86	-0.06	-0.06
Intangible Assets	-0.43	0.14	-0.59	-0.3	-0.18	-0.4	0.43	0.21	-0.25	-0.18	0.14	-0.75	-0.22	-0.09	0.12	-0.6	-0.27	-0.12	-0.43	0.27		-0.4	-0.25	0.49	-0.37	-0.37
Common Stock	0.75	0.38	0.77	0.67	-0.1	0.54	-0.26	-0.64	0.6	0.33	0.41	0.55	0.79	0.56	0.42	0.68	0.6	0.58	0.74	0.27	-0.4		-0.02	-0.25	0.72	0.72
Net Tangible Assets	0.34	-0.81	-0.01	-0.58	0.98	-0.54	-0.95	0.64	-0.62	-0.44	-0.8	0.07	0.16	-0.57	-0.81	0.15	-0.65	-0.71	0.36	-0.81	-0.25	-0.02		-0.78	0.38	0.38
Short Long Term Debt	-0.44	0.67	-0.37	0.38	-0.81	0.16	0.87	-0.32	0.47	0.28	0.62	-0.35	-0.23	0.2	0.6	-0.46	0.39	0.49	-0.45	0.86	0.49	-0.25	-0.78		-0.43	-0.43
Cash	0.98	0.19	0.61	0.44	0.3	0.3	-0.61	-0.35	0.38	0.21	0.22	0.58	0.7	0.36	0.22	0.69	0.35	0.35	0.98	-0.06	-0.37	0.72	0.38	-0.43		1.0
Cash And Short Term Investments	0.98	0.19	0.61	0.44	0.3	0.3	-0.61	-0.35	0.38	0.21	0.22	0.58	0.7	0.36	0.22	0.69	0.35	0.35	0.98	-0.06	-0.37	0.72	0.38	-0.43	1.0

Click cells to compare fundamentals

Faron Pharmaceuticals Account Relationship Matchups

Faron Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.2M	8.4M	13.2M	11.3M	10.2M	10.5M
Short Long Term Debt Total	2.8M	3.2M	3.5M	13.3M	13.1M	13.8M
Other Current Liab	2.8M	4.1M	4.3M	3.3M	2.4M	2.7M
Total Current Liabilities	6.1M	6.5M	7.2M	10.5M	15.0M	15.8M
Total Stockholder Equity	1.6M	(1.8M)	2.9M	(11.5M)	(15.2M)	(14.4M)
Net Debt	(4.2M)	(883K)	(3.3M)	6.3M	6.2M	6.5M
Retained Earnings	(80.0M)	(96.6M)	(116.3M)	(143.7M)	(172.2M)	(163.6M)
Accounts Payable	3.0M	2.1M	2.2M	5.1M	9.0M	9.4M
Non Current Assets Total	1.0M	996K	1.2M	1.5M	1.4M	1.3M
Long Term Debt	2.3M	2.7M	2.9M	11.1M	9.4M	9.9M
Net Receivables	1.3M	1.3M	1.4M	905K	1.0M	981.9K
Common Stock Shares Outstanding	39.9K	46.8K	51.8K	60.1K	68.8K	40.5K
Liabilities And Stockholders Equity	10.2M	8.4M	13.2M	11.3M	10.2M	10.5M
Non Current Liabilities Total	2.5M	3.7M	3.1M	12.3M	10.4M	10.9M
Other Current Assets	2.1M	3.3M	5.2M	2.7M	2.0M	2.5M
Other Stockholder Equity	78.8M	91.9M	(1K)	129.4M	154.2M	161.9M
Total Liab	8.6M	10.2M	10.3M	22.7M	25.4M	26.7M
Total Current Assets	9.2M	7.4M	12.0M	9.7M	8.9M	9.2M
Accumulated Other Comprehensive Income	78.9K	92.0K	116.5K	129.5K	154.4K	162.1K
Intangible Assets	529K	565K	899K	1.2M	1.1M	691.5K
Net Tangible Assets	1.1M	(2.4M)	2.0M	(12.6M)	(11.4M)	(10.8M)
Short Long Term Debt	163K	122K	429K	1.9M	3.5M	3.6M
Cash	7.1M	4.1M	6.9M	7.0M	6.9M	5.4M
Cash And Short Term Investments	7.1M	4.1M	6.9M	7.0M	6.9M	5.4M
Property Plant And Equipment Net	399K	375K	207K	327K	204K	195.6K
Property Plant And Equipment Gross	399K	375K	207K	327K	225K	198.1K
Property Plant Equipment	399K	375K	207K	327K	376.1K	192.0K
Non Currrent Assets Other	77K	56K	53K	60K	54K	51.3K
Net Invested Capital	4.0M	1.0M	6.3M	1.5M	(2.3M)	(2.1M)
Net Working Capital	3.1M	868K	4.8M	(741K)	(6.1M)	(5.8M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Faron Stock Analysis

When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Faron Change To Operating Activities vs Capital Expenditures Analysis

Change To Operating Activities vs Capital Expenditures

Change To Operating Activities vs Capital Expenditures Correlation Analysis

Correlation Coefficient

Change To Operating Activities

Capital Expenditures

Faron Pharmaceuticals fundamental ratios Correlations

Faron Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Faron Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Faron Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Current Liabilities Total	+ 1.0	Long Term Debt
Cash And Short Term Investments	+ 1.0	Cash
Long Term Debt	+ 0.99	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Cash	+ 0.98	Total Assets

Net Tangible Assets	- 0.95	Net Debt
Retained Earnings	- 0.95	Total Current Liabilities
Total Liab	- 0.94	Retained Earnings
Common Stock Shares Outstanding	- 0.92	Retained Earnings
Retained Earnings	- 0.92	Current Deferred Revenue
Net Debt	- 0.92	Total Stockholder Equity